Mammaglobin A DNA vaccine

Drug Profile

Mammaglobin A DNA vaccine

Alternative Names: WUSM-MGBA-01

Latest Information Update: 17 Mar 2016

Price : $50

At a glance

  • Originator Corixa Corporation
  • Developer Washington University School of Medicine
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 01 Jan 2015 Washington University School of Medicine initiates a phase I trial for Breast cancer in USA (NCT02204098)
  • 01 Dec 2014 Washington University School of Medicine completes a phase I trial in Breast cancer in USA (NCT00807781)
  • 01 Oct 2009 Phase-I clinical trials in Breast cancer in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top